Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived stem cells in Crohn's fistula
NCT04612465Phase 3Active, not recruiting
- Sponsor
- Anterogen Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous adipose-derived mesenchymal stromal cells in Crohn's disease, sponsored by Anterogen Co., Ltd.. Started Jan 2020; status: active, not recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04612465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612465.